17965-82-1

Usage

Uses

1,7-Naphthyridin-8-amine is a useful chemical in organic synthesis.

InChI:InChI=1/C6H4F3NO3/c1-2-10-3(5(11)12)4(13-2)6(7,8)9/h1H3,(H,11,12)

Upstream product

• 253-69-0 [1,7]naphthyridine 
• 452-58-4 2,3-Diaminopyridine 
• 56-81-5 glycerol 

Downstream Products

• 67967-11-7 8-hydroxy-1,7-naphthyridine 
• 1201802-79-0 C₁₇H₁₃N₃O₂S 
• 1351516-28-3 8-imino-1,7-naphthyridin-7(8H)-amine 2,4,6-trimethylbenzenesulfonate 
• 651310-81-5 7-benzenesulfonyl-6-methylsulfanyl-4,5,8atriaza-phenanthren-8-ylideneamine monotrifluoroacetate 
• 67967-17-3 8-amino-5-bromo-1,7-naphthyridine 
• 909649-06-5 5-bromo-8-chloro-[1,7]naphthyridine 
• 13058-77-0 8-chloro-[1,7]naphthyridine 
• 958254-67-6 1,2,3,4-tetrahydro-1,7-naphthyridin-8-amine 

Relevant academic research and scientific papers

ALPHA, BETA-UNSATURATED AMIDE COMPOUND

An object of the present invention is to provide an α,β-unsaturated amide compound or a pharmaceutically acceptable salt or the like thereof having anticancer activity and the like. The α,β-unsaturated amide compound represented by the following formula (I) or a pharmaceutically acceptable salt or the like thereof has anticancer activity and the like: [wherein, "A" represents optionally substituted heterocyclic diyl, R1 represents hydrogen atom or optionally substituted lower alkyl, R2 represents optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted aliphatic heterocyclic group or optionally substituted aromatic heterocyclic group, X represents -O-, -S-, -SO2-, -NRX1- (wherein, RX1 represents hydrogen atom or lower alkyl), -CHRX2- (wherein, RX2 represents hydrogen atom or hydroxy), -CH=CH-, -CO- or -NH-CO-, and n1 and n2 are the same or different, and each represents 0 or 1].

HETEROARYL COMPOUNDS AS CXCR4 INHIBITORS, COMPOSITION AND METHOD USING THE SAME

The present disclosure provides heteroaryl compounds of Formula (I), processes for their preparation, pharmaceutical compositions containing them, and their use in the treatment of diseases and disorders, arising from or related to the CXCR4 pathway.

a, ? UNSATURATED AMIDE COMPOUND

The present invention provides an α,β-unsaturated amide compound or a pharmaceutically acceptable salt or the like thereof having anticancer activity and the like represented by the following formula (I): [wherein, "A" represents optionally substituted heterocyclic diyl, R1 represents hydrogen atom or optionally substituted lower alkyl, R2 represents optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted aliphatic heterocyclic group or optionally substituted aromatic heterocyclic group, X represents -O-, -S-, -SO2-, -NRX1- (wherein, RX1 represents hydrogen atom or lower alkyl), -CHRX2- (wherein, RX2 represents hydrogen atom or hydroxy), -CH=CH-, -CO- or -NH-CO-, and n1 and n2 are the same or different, and each represents 0 or 1].

1-SUBSTITUTED 1,2,3,4-TETRAHYDRO-1,7-NAPHTHYRIDIN-8-AMINE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR ANTAGONISTS

The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof has an EP4 receptor antagonistic action, and is useful as an agent for the prophylaxis or treatment of EP4 receptor associated diseases (e.g., rheumatoid arthritis, aortic aneurysm (e.g. abdominal aortic aneurysm, thoracic aortic aneurysm, thoracoabdominal aortic aneurysm etc.), endometriosis, ankylosing spondylitis, inflammatory breast cancer etc.) and the like.

HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF

Provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as CNS disorders and metabolic disorders, including, but not limited to, e.g., neurological disorders, psychosis, schizophrenia, obesity, and diabetes.

HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF

Provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as CNS disorders and metabolic disorders, including, but not limited to, e.g., neurological disorders, psychosis, schizophrenia, obesity, and diabetes

Chichibabin Amination of 1,X-Naphthyridines. Nuclear Magnetic Resonance Studies on the ? Adducts of Heterocyclic Systems with Nucleophiles

In the amination of 1,X-naphthyridines with potassium amide in liquid ammonia at about -35 to -40 deg C the initial adduct formation is charge controlled.Thus, at these temperatures the site with the lowest electron density is most susceptible for amide attack (C-2 in 1,5-naphthyridine, C-2 in 1,6-naphthyridine, C-2 and C-8 in 1,7-naphthyridine, and C-2 in 1,8-naphthyridine), as proven by NMR spectroscopy.When the temperature was raised to about 10 deg C, the site of addition has been found to change for 1,5- and 1,7-naphthyridine (NMR spectroscopy): from C-2 to C-4 in 1,5-naphthyridine and from C-2 and C-8 to C-8 only in 1,7-naphthyridine.In case of 1,6- and 1,8-naphthyridines no change was observed.Thus, the amination at about 10 deg C is a process which is thermodynamically controlled.The several factors which contribute to the stability of these addition products have been discussed.It has been found that the anionic ? adducts 2(4,8)-aminodihydro-1,X-naphthyridinides can be easily oxidized with potassium permanganate into their corresponding 2(4,8)-amino-1,X-naphthyridines.